17-Oct-2026 19:13:47
HEMORGANICGeneral news
HEMO ORGANIC: NO DEVIATION IN USE OF RS 4.25 CR PREFERENTIAL WARRANT PROCEEDS
• 34,00,000 convertible warrants converted into equal number of equity shares at ₹12.50 each on 25 September 2026. • ₹4.25 Cr raised via preferential warrants; ₹3.18 Cr utilised, ₹1.09 L left for general corporate purpose. • Also filed unaudited Q2/H1 FY27 results with limited review report. Impact: no deviation indicated in use of preferential warrant proceeds; Q2/H1 FY27 results also filed.
Hemo Organic Ltd
Open attachment